LEGISLATIVE FISCAL ESTIMATE
ASSEMBLY, No. 2288
STATE OF NEW JERSEY
222nd LEGISLATURE
DATED: FEBRUARY 23, 2026
SUMMARY
Synopsis:
PRE-FILED FOR INTRODUCTION IN THE 2026 SESSION
Sponsored by:
Assemblywoman MARGIE DONLON, M.D.
District 11 (Monmouth)
Assemblyman STERLEY S. STANLEY
District 18 (Middlesex)
Assemblywoman ROSAURA "ROSY" BAGOLIE
District 27 (Essex and Passaic)
Co-Sponsored by:
Assemblyman Scharfenberger
SYNOPSIS
Establishes licensure requirement for source plasma donation centers.
Type of Impact:
Annual increase in State expenditures and revenues.
Agencies Affected:
Department of Health, Judiciary.
CURRENT VERSION OF TEXT
As reported by the Assembly Regulated Professions Committee with technical review.
An Act concerning licensure of source plasma donation centers and supplementing Title 26 of the Revised Statutes.
Be It Enacted by the Senate and General Assembly of the State of New Jersey:
Office1. ofThe LegislativeLegislature Servicesfinds Estimateand declares that:
Fiscal Impact
Annual
State Expenditure Increase
Indeterminate
State Revenue Increase
Indeterminate
· The Office of Legislative Services (OLS) concludes that Department of Health costs will increase by an indeterminate amount annually to establish and enforce a separate licensure and regulatory system for source plasma donation centers, which are currently regulated by the department as blood banks.
· Based on an analysis conducted by the California Legislature of AB 725 (2025), the OLS concludes that the department will face indeterminate up-front costs to hire additional staff and develop or purchase an information technology platform for the source plasma donation licensing program. These costs will be incurred prior to the point at which the department will begin collecting applicants’ licensing fees.
· Given that the OLS cannot anticipate either the amount of the initial or renewal licensing fees that the department will charge, or the number of license applicants, the magnitude of the bill’s revenue impact is indeterminate.
· State revenues will further increase, albeit by an indeterminate amount, attributable to penalties paid by licensed source plasma donation centers that are found to be in violation of the bill’s provisions.
BILL DESCRIPTION
The bill requires source plasma donation centers to apply annually for a license from the Department of Health in order to operate within the State and directs the department to establish the process by which source plasma donation center operators will apply for licensure, as well as the requisite initial and renewal licensure fees. The initial licensure fee for a source plasma donation center that is operating prior to the bill’s effective date will be $25. The income received from the licensure and renewal fees will be appropriated to the department to implement the bill’s requirements.
The department will promulgate rules and regulations governing the donations of source plasma, in accordance with federal regulations and voluntary industry standards. The department is authorized to enter and inspect any source plasma donation center, and to investigate the center’s premises, books, and records.
The department is authorized to enforce violations of the licensure standards established under the bill, and to suspend, revoke, and refuse to grant a license to an applicant. A licensee may request a hearing on a disputed violation, with the department rendering a decision on the violation within 48 hours. If the department rules against the licensee, the licensee may apply for injunctive relief in the Superior Court of New Jersey. Under the bill, first-time violators will be assessed a penalty ranging from $100 to $1,000, while repeat offenders will face a fine ranging between $500 and $5,000.
FISCAL ANALYSIS
EXECUTIVE BRANCH
None received.
OFFICE OF LEGISLATIVE SERVICES
The OLS concludes that Department of Health expenditures will increase by an indeterminate amount annually to establish and enforce a separate licensure and regulatory system for source plasma donation centers, which are currently regulated by the department as blood banks. To the extent that the department’s enforcement of the newly established source plasma donation center licensing requirements results in an increased number of applications for injunctive relief in the Superior Court of New Jersey, as permitted under the bill, costs to the Judiciary may increase.
The OLS assumes that the department will establish initial and renewal licensure fees at the level necessary to support the department’s costs for personnel and information technology infrastructure necessary to regulate the State’s source plasma donation centers. However, the OLS cannot anticipate either the amount of the licensing fee that the department will establish, or the number of applicants for licensure.
State revenues will further increase, albeit by an indeterminate amount, attributable to penalties paid by licensed source plasma donation centers that are found to be in violation of the bill’s provisions. Given that the bill provides for a range of penalties, which will depend upon the severity and frequency of the violations, the OLS cannot determine the amount by which penalty collections will affect State revenues.
For context, an analysis by the California Assembly Committee on Appropriations of AB 725 (2025), which requires the California Department of Public Health (CDPH) to establish a licensing and enforcement program for source plasma donation centers, projects that the CDPH will incur $3.7 million in additional costs in each of the first two years following the bill’s effective date, and $2.53 million in annual costs thereafter to hire additional staff, promulgate regulations, and establish an information technology platform for the licensing program. Although AB 725 specifies that the licensing application fee will be set at an amount to cover CDPH costs to administer the licensing program, the analysis notes that the CDPH will incur substantive costs before it can begin collecting licensing fees.
The OLS concludes that the department will similarly face indeterminate up-front costs to hire additional staff and develop or purchase an information technology platform for the source plasma donation licensing program. These costs will be incurred prior to the point at which the department will begin collecting applicants’ licensing fees. Since the department’s Office of Clinical Laboratory Improvement Services currently licenses and regulates source plasma donation centers as blood banks, the department could potentially minimize costs for the source plasma donation center licensing program by reassigning certain staff who have blood bank regulatory expertise to the new licensing program. Similarly, to the extent that the department can adapt existing information technology platforms used by the blood bank licensing program to the source plasma donation center licensing program, State costs may be reduced.
Under existing statutes and regulations, the department assesses a licensure fee of $100 from blood banks that serve as collection centers, plus a variable fee that is based upon the annual number of collections made by the facility. These variable fees range from $250 for a facility that performs up to 200 collections annually to $1,900 for a facility that makes more than 50,000 collections annually.
A source plasma donation center is a facility, other than a blood bank, which utilizes plasmapheresis to separate the fluid portion of human blood for use as source material for plasma protein therapies. Plasma protein therapies are used to treat a variety of medical conditions, many of which are rare genetic conditions. Source plasma donation centers are regulated by the federal Food and Drug Administration, in addition to the department. Moreover, the International Quality Plasma Program, which is operated by the Plasma Protein Therapeutics Association, offers a voluntary certification program for source plasma donation centers. According to a search of an association database, 12 source plasma donation centers currently operate in the State.
Section:
Human Services
Analyst:
Anne Cappabianca
Senior Fiscal Analyst
Approved:
Thomas Koenig
Legislative Budget and Finance Officer
This legislative fiscal estimate has been produced by the Office of Legislative Services due to the failure of the Executive Branch to respond to our request for a fiscal note.
This fiscal estimate has been prepared pursuant to P.L.1980, c.67 (C.52:13B-6 et seq.).
a. The clinical need for plasma-derived therapies has been steadily increasing for many years.
b. Plasma-derived therapies are often the only therapies for many rare and chronic conditions such as primary immune deficiencies and bleeding disorders.
c. Plasma-derived therapies also treat acute blood loss, burns, and sepsis.
d. Donors at source plasma donation centers provide the source plasma necessary to manufacture plasma-derived therapies;
e. Source plasma donation centers employ thousands of New Jersey residents and provide millions of dollars to local economies through wages, taxes, and donor fees.
f. Source plasma donation centers provide excellent opportunities for entry-level jobs for high school graduates.
g. As recently as 2019, the federal Food and Drug Administration declared a shortage of immune globulin, a plasma-derived therapy.
h. A leading analyst predicts the number of source plasma donation centers will increase from more than 1200 in 2024 to more than 1800 in 2030.
i. It is in the best interest of the State to create a unique licensure for source plasma donation centers.
2. For the purposes of this act:
“Commissioner” means the Commissioner of Health.
“Department” means the Department of Health.
“Licensee” means a person holding a license under the provisions of this act.
“Person” means a natural person, partnership, association, corporation, cooperative, institution, sole proprietorship, agency, limited liability partnership or company, or other similar entity authorized to transact business in this State.
“Plasmapheresis” means a procedure by which, during a single visit to a source plasma donation center, blood is removed from an individual, the source plasma is separated from the formed elements, and at least the red blood cells are returned to the donor.
“Source plasma” means the fluid portion of human blood collected by plasmapheresis and intended as source material for plasma protein therapies. It does not include single donor plasma products intended for intravenous use.
“Source plasma donation center” means a facility other than a blood bank where source plasma is collected by plasmapheresis.
3. a. A person shall not operate or conduct a source plasma donation center in this State unless duly licensed by the commissioner under the provisions of this act. A license required by this act shall be in addition to any other license or permit required by any local board of health or other body exercising the powers of such a board in any municipality in this State, except that any source plasma donation center receiving source plasma donations by plasmapheresis and performing only non-diagnostic donor screening tests shall not need a blood bank or clinical laboratory license.
b. A license issued pursuant to this act shall expire on December 31 in each calendar year and application for renewal therefor shall be made on or before November 10 on forms provided by the department. The original or a certified copy of the license shall be conspicuously displayed by the licensee at the premises occupied as a source plasma donation center.
c. The commissioner shall establish the fee necessary to accompany the initial licensure application and each renewal thereof, except the license fee for any person who has been operating a source plasma donation center prior to the effective date of this act and upon submission of a properly completed application form shall pay an initial application fee of $25. Upon expiration of the initial license, the owner of the source plasma donation center shall be subject to the licensure fees as set by the commissioner.
d. The commissioner may, pursuant to the “Administrative Procedure Act,” P.L.1968, c.410 (C.52:14B-1 et seq.), establish and periodically increase the application and renewal fees to reflect increased State costs in source plasma donation center licensure operations.
e. The income received from licensure and renewal fees pursuant to this section shall be appropriated to the department to effectuate the purposes of this act.
4. a. The commissioner shall promulgate rules and regulations, to promote the safety and best practices among source plasma donation centers, pursuant to the “Administrative Procedure Act,” P.L.1968, c.410 (C.52:14B-1 et seq.), governing the donation of source plasma, including, but not limited to, rules governing staff supervision, training, and duties, including requirements for plasmapheresis and pre-donation screening tests in accordance with: (1) 42 C.F.R. Part 493; (2) 21 C.F.R. parts 600 through 640; and (3) the Plasma Protein Therapeutics Association Voluntary Standards Program.
b. The commissioner shall have the power and authority to enter and inspect any source plasma donation center and to make such investigation of the premises and the books and records as is reasonably necessary to carry out the provisions of this act.
c. The commissioner shall enforce the provisions of this act and may make complaints against persons violating its provisions or the rules or regulations issued thereunder and prosecute violations of same. The commissioner may suspend or revoke any license issued for a violation of any of the provisions of this act.
d. The commissioner, before refusing to grant a license, or before suspending or revoking a license previously granted, except as hereafter provided in section 5 of this act, shall give notice to the applicant or licensee personally, or by mail addressed to the applicant or licensee at the applicant’s or licensee’s last known address, and afford the applicant or licensee an opportunity to be heard with respect thereto at a time and place specified in such notice. The applicant or licensee shall have the right to be heard in person or by attorney, and to offer evidence pertinent to the subject of the hearing. A duly certified copy of the order of the commissioner issued as a result of such hearing shall be served on the applicant or licensee by mail personally addressed the applicant or licensee at the applicant’s or licensee’s last known address, except if such applicant or licensee is a corporation, then the order shall be served in the same manner upon any officer of registered agent of the corporation.
5. a. It shall be a violation of this act for any person to obstruct, hinder, delay, or interfere, by force or otherwise, with the performance by the commissioner of any duty under the provisions of this act. If the commissioner shall have reason to believe that a condition exists or has occurred at a source plasma donation center, in violation of the provisions of this act, which is dangerous to the public health, the commissioner may order such source plasma donation center to correct such violation and may suspend the license of the source plasma donation center until the correction is completed. If a licensee denies the existence or occurrence of a violation, the licensee may apply to the commissioner for a hearing. The hearing shall be held and a decision rendered within 48 hours of the receipt of the request for a hearing. If the commissioner rules against the licensee, the licensee shall have the right to apply for injunctive relief against the commissioner’s order. Jurisdiction for such injunctive relief shall be in the Superior Court of New Jersey.
b. Any person who violates the provisions of this act or an order of the commissioner issued pursuant to this act, shall be liable to a penalty of not less than $100 but not more than $1,000 for the first offense, and for the second and each succeeding offense, a penalty of not less than $500 but not more than $5,000, to be established by the commissioner. The penalties herein provided shall be enforced by the department as plaintiff in a summary proceeding in accordance with the “Penalty Enforcement Law of 1999,” P.L.1999, c.274 (C.2A:58-10 et seq.).
6. This act shall take effect on November 1 next following the date of enactment except that the Commissioner of Health may take any anticipatory administrative action in advance as shall be necessary for the implementation of this act.